Contact
Contact
About

The ambition behind QUIDDITAS Therapeutics

A constant effort needs to be maintained to propose new treatments for genetic disorders.

In this context, QUIDDITAS seeks to propel its flagship technology GREAT as a reference in the genome editing field.

Our major concern is to offer therapeutic responses to diseases currently considered as uncurable and bring hope for patients through broadly available off-the-shelf therapies, with the dual consideration of security and transparency.

Founding & Management team

François Cherbonneau, Ph.D.

CEO, co-founder and inventor of the technology

Co-founded QUIDDITAS Therapeutics in 2021 to develop a disruptive genome recombination technology.

Holds a PhD in Biotechnologies/Genetics from a co-thesis program between Université de Paris and Massachusetts General Hospital/Harvard Medical School, and an engineering degree in Biotechnologies from Ecole de Biologie Industrielle. His management training is from the HEC Paris (Challenge +).

More than 5 years of experience in molecular designs for sequencing and genome editing technologies.

Aurore Cherbonneau Prunevieille, Ph.D.

COO and co-founder

Co-founded QUIDDITAS Therapeutics in 2021.

Holds a PhD in Biotechnologies/Immunology from a co-thesis program between Université de Paris and Massachusetts General Hospital/Harvard Medical School, and an engineering degree in Biotechnologies from Ecole de Biologie Industrielle. Her management training is from the HEC Paris (Challenge +).

More than 5 years of experience in Immunology and preclinical studies.

Our company

Triangle

An inclusive scientific environment

A French company strategically located

 

The company is based in the south of the Paris area and is easily accessible from the main french hubs (CDG and Orly). QUIDDITAS benefits from a strong scientific interaction as it is a member of the main french technology cluster of Paris Saclay, one of the biggest european research organization with a top-ranked university.

Ethical considerations

 

As the development of biotechnologies requires new challenges, the industries of the field need to accentuate their effort in terms of ethics and reglementation respect. QUIDDITAS takes these questions of security and well-being of the patient very seriously, with a constant transparency and a close supervision of the governemental regulatory agencies.

Latest news